Perrigo/$PRGO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Perrigo
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
- Ticker
- $PRGO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 8,100
- Headquarters
- Dublin, Ireland
- Website
- www.perrigo.com
Perrigo Metrics
BasicAdvanced
$2.2B
-
-$12.49
0.60
$1.16
7.35%
Price and volume
Market cap
$2.2B
Beta
0.6
52-week high
$21.01
52-week low
$9.23
Average daily volume
2.6M
Dividend rate
$1.16
Financial strength
Current ratio
2.324
Quick ratio
1.09
Long term debt to equity
1.305
Total debt to equity
1.382
Interest coverage (TTM)
1.40%
Profitability
EBITDA (TTM)
615.5
Gross margin (TTM)
33.26%
Net profit margin (TTM)
-41.85%
Operating margin (TTM)
6.75%
Effective tax rate (TTM)
-5.62%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
1.97%
Return on equity (TTM)
-48.75%
Valuation
Price to revenue (TTM)
0.529
Price to book
0.87
Price to tangible book (TTM)
-1.6
Price to free cash flow (TTM)
17.555
Free cash flow yield (TTM)
5.70%
Free cash flow per share (TTM)
0.899
Dividend yield (TTM)
7.35%
Forward dividend yield
7.35%
Growth
Revenue change (TTM)
-4.19%
Earnings per share change (TTM)
2,047.94%
3-year revenue growth (CAGR)
-3.62%
10-year revenue growth (CAGR)
-2.47%
3-year earnings per share growth (CAGR)
192.09%
10-year earnings per share growth (CAGR)
5.85%
3-year dividend per share growth (CAGR)
2.86%
10-year dividend per share growth (CAGR)
7.95%
What the Analysts think about Perrigo
Analyst ratings (Buy, Hold, Sell) for Perrigo stock.
Analyst projections of the future price of Perrigo stock.
Bulls say / Bears say
Perrigo gained 50 basis points of share in U.S. store-brand OTC and in key European brands, despite weaker category markets. Continued share gains could help it benefit when consumer demand improves. (Perrigo)
The company expects its Operational Enhancement Program to deliver $80 million to $100 million in annual savings by 2027. A further tailwind is the expected easing of factory under-absorption in the second half, which weighed on 2026 earnings. (The Motley Fool, Perrigo)
Perrigo used most of the $359 million proceeds from its Dermacosmetics sale to repay debt, while continuing reviews of its Infant Formula and Oral Care businesses. These actions could simplify the portfolio and improve financial flexibility. (Perrigo)
Core organic sales fell 3.5% in the second quarter as category demand remained soft and retailers reduced inventories; core adjusted EPS fell 20.7%. Sales declines and lower volumes also pushed core adjusted gross margin down 250 basis points. (Perrigo)
Perrigo had $3.3 billion of debt and net leverage of about four times adjusted EBITDA at the end of June. That leaves limited room for error and makes debt reduction and refinancing important risks for shareholders. (Perrigo)
Legacy talc litigation remains a material uncertainty: Perrigo reported about 220 pending lawsuits and roughly 115 new complaints in the first half of 2026, with more than 30 trials scheduled through year-end. The company also disclosed that the IRS is seeking transfer-pricing adjustments for 2016–19, which it is contesting. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
Perrigo Financial Performance
Revenues and expenses
Perrigo Earnings Performance
Company profitability
Upcoming events
Perrigo News
AllArticlesVideos
Funds containing Perrigo
Fund name | Fund size | $PRGO weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.12% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.12% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.11% |
SPDR S&P US Dividend Aristocrats€SPYD | $3.8B | 0.09% |
SPDR S&P US Dividend Aristocrats£USDV | $3.8B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.